Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer’s Disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Current information is scarce regarding comorbid conditions, treatment, survival, institutionalization, and health care utilization for Alzheimer's disease (AD) patients. OBJECTIVES: Compare all-cause mortality, rate of institutionalization, and economic burden between treated and untreated newly-diagnosed AD patients. METHODS: Patients aged 65-100 years with ≥1 primary or ≥2 secondary AD diagnoses (ICD-9-CM:331.0] with continuous medical and pharmacy benefits for ≥12 months pre-index and ≥6 months post-index date (first AD diagnosis date) were identified from Medicare fee-for-service claims 01JAN2011-30JUN2014. Patients with AD treatment claims or AD/AD-related dementia diagnosis during the pre-index period were excluded. Patients were assigned to treated and untreated cohorts based on AD treatment received post-index date. Total 8,995 newly-diagnosed AD patients were identified; 4,037 (44.8%) were assigned to the treated cohort. Time-to-death and institutionalization were assessed using Cox regression. To compare health care costs and utilizations, 1 : 1 propensity score matching (PSM) was used. RESULTS: Untreated patients were older (83.85 versus 81.44 years; p < 0.0001), with more severe comorbidities (mean Charlson comorbidity index: 3.54 versus 3.22; p < 0.0001). After covariate adjustment, treated patients were less likely to die (hazard ratio[HR] = 0.69; p < 0.0001) and were associated with 20% lower risk of institutionalization (HR = 0.801; p = 0.0003). After PSM, treated AD patients were less likely to have hospice visits (3.25% versus 9.45%; p < 0.0001), and incurred lower annual all-cause costs ($25,828 versus $30,110; p = 0.0162). CONCLUSION: After controlling for comorbidities, treated AD patients have better survival, lower institutionalization, and sometimes fewer resource utilizations, suggesting that treatment and improved care management could be beneficial for newly-diagnosed AD patients from economic and clinical perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“4 million US patients are currently diagnosed with AD, with about 5 million patients over age 65 [2, 3].”
Hibbard, J. H., & Greene, J. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1061 · Cited by 1,787
Missed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors
Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P., & Singh, H. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181a6bebc · Cited by 969 · cited 1×
“Early detection of dementia is beneficial to provide timely care and offer direct benefits to patients with dementia [17].”
Charlson, M. E., Charlson, R. E., Peterson, J. C., Marinopoulos, S. S., Briggs, W. M., & Hollenberg, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.01.006 · Cited by 894 · cited 2×
“Studies on hospital data have suggested that early and timely detection of AD can be cost-saving [6, 10, 22].”
Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
Zhao, Y., Kuo, T.-C., Weir, S., Kramer, M. S., & Ash, A. S. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-108 · Cited by 196 · cited 1×
“Other studies examining the economic burden of AD have only assessed prevalent cases and have not compared the current economic burden among treated and untreated AD patients [7, 8].”
Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare
Hill, J. W., Futterman, R., Duttagupta, S., Mastey, V., Lloyd, J. R., & Fillit, H. (2002) · Neurology · doi:10.1212/wnl.58.1.62 · Cited by 181
Self-citationLin, P., Zhong, Y., Fillit, H. M., Chen, E., & Neumann, P. J. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14227 · Cited by 127
Self-citationSuehs, B. T., Davis, C. D., Alvir, J., van Amerongen, D., PharmD, N. C. P., Joshi, A. V., Faison, W. E., & Shah, S. N. (2013) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317513488911 · Cited by 71
Cited by
Alzheimer’s Disease – Why We Need Early Diagnosis
Rasmussen, J., & Langerman, H. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s228939 · Cited by 501
“27 After controlling for comorbidities, the treated cohort had better survival and a 20% lower rate of institutionalisation.”
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
“Nonetheless, the extent of utility needed to justify clinical adoption of this technique is a complex matter that requires to consider both the therapeutic implications and the wider health-economic impact including care planning, hospitalization, additional clinical time and possible alternative diagnosis methods ava…”
BackgroundKnowledge about Alzheimer's disease in the Brazilian population
Amado, D. K., & Brucki, S. M. D. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20180106 · Cited by 68
Mahmoudi, E., Sadaghiyani, S., Lin, P., Kamdar, N., Norcott, A., Peterson, M. D., & Meade, M. A. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103351 · Cited by 32
Paolillo, E. W., Casaletto, K. B., Clark, A. L., Taylor, J. C., Heuer, H. W., Wise, A. B., Dhanam, S., Sanderson-Cimino, M., Saloner, R., Kramer, J. H., et al. (2024) · JMIR Aging · doi:10.2196/52831 · Cited by 16
“The timely detection of neurodegenerative diseases such as FTLD is a core public health strategy to reduce the individual, caregiver, and socioeconomic burden of dementia [5-7].”
Background
Metadata
- Authors
- Black, C. M., Fillit, H., Xie, L., Hu, X., Kariburyo, M. F., Ambegaonkar, B. M., Baser, O., Yuce, H., & Khandker, R. K.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-28
- Volume
- 61
- Issue
- 1
- Pages
- 185-193
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2765174431
- Cited by
- 46
- References
- 8
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer’s Disease. https://app.cochat.ai/papers/10.3233/jad-170518
- The paper
- Black, C. M., Fillit, H., Xie, L., Hu, X., Kariburyo, M. F., Ambegaonkar, B. M., Baser, O., Yuce, H., & Khandker, R. K. (2017). Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer’s Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-170518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.